Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 647 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lipid panel Clear all
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766
View directory record Official record
Conditions
Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

NCT00701636
View directory record Official record
Conditions
Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions
daptomycin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
19 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dose-Response Effect of Phosphatidylserine on eSport Performance

NCT07533032
View directory record Official record
Conditions
Cognitive Function, Gaming Performance
Interventions
Placebo, Phosphatidylserine (100 mg), Phosphatidylserine (200 mg)
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

NCT00322101
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
total-body irradiation, allogeneic hematopoietic stem cell transplantation, cyclophosphamide, mycophenolate mofetil, busulfan, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, cytogenetic analysis, flow cytometry, fluorescence in situ hybridization, pharmacological study, polymorphism analysis, tacrolimus, methotrexate
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Denver, Colorado • Altanta, Georgia • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery

NCT01059019
View directory record Official record
Conditions
Refractive Error
Interventions
Omega-3 Fatty Acid Supplements
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 28 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 9, 2026, 3:22 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Results available

Use of Aromatherapy to Reduce Symptom Burden

NCT05251337
View directory record Official record
Conditions
Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions
Essential oils, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 9, 2026, 3:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure

NCT00468299
View directory record Official record
Conditions
Early Pregnancy Failure, Miscarriage, Fetal Demise, Anembryonic Pregnancy
Interventions
Misoprostol and placebo, Mifepristone and misoprostol
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 9, 2026, 3:22 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

NCT01817127
View directory record Official record
Conditions
Healthy, Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 9, 2026, 3:22 PM EDT
Terminated Not applicable Interventional

Omega-3 Fatty Acid Supplements and Dry Eye

NCT01213342
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Omega-3 Fatty Acid, Soybean Soft Gels
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 9, 2026, 3:22 PM EDT
Not listed Not applicable Interventional

Effect of Vitamin D Status and Repletion on Postoperative Total Joint Arthroplasty Complications

NCT04229368
View directory record Official record
Conditions
Hip Arthropathy, Knee Arthropathy, Vitamin D Deficiency
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 9, 2026, 3:22 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance.

NCT07397273
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
L-Alpha glycerylphosphorylcholine, Microcrystalline Cellulose
Dietary Supplement
Lead sponsor
Northern Illinois University
Other
Eligibility
19 Years to 29 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 9, 2026, 3:22 PM EDT
Terminated Not applicable Interventional Results available

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929
View directory record Official record
Conditions
Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions
Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Nutritional Technology for Vitamin D Absorption

NCT06266702
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
Experimental Oil with Phospholipids, Control Polyunsaturated Oil Blend
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
North Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 9, 2026, 3:22 PM EDT
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 75 Years
Enrollment
15,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional

Osteoporosis Prevention After Heart Transplant

NCT00000412
View directory record Official record
Conditions
Osteoporosis, Cardiac Transplantation
Interventions
Alendronate, Calcitriol, Placebo Alendronate, Placebo Calcitriol
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Results available

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

NCT02786498
View directory record Official record
Conditions
Fracture
Interventions
Vitamin D3, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 1 Interventional

Pain Medications Following Thyroidectomy and Parathyroidectomy

NCT03640247
View directory record Official record
Conditions
Thyroid Disease, Parathyroid Diseases
Interventions
Non-narcotic group regimen, Narcotic group regimen
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821
View directory record Official record
Conditions
Huntington Disease
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 9, 2026, 3:22 PM EDT
Completed Phase 1 Interventional Results available

Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.

NCT01190020
View directory record Official record
Conditions
Chronic Constipation, Methanogenesis
Interventions
Lubiprostone, Lubiprostone Control
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 9, 2026, 3:22 PM EDT